The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

Things are going from bad to worse for the pharmaceutical giant.

A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.

Pfizer (NYSE:PFE) oncology updates and IBRANCE expansion unfold within S&P 500 healthcare segment, alongside lung cancer ...

The study was originally meant to be published in a CDC weekly report in March.

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share ...

Pfizer (PFE) stock is in focus as the FDA approves a label expansion therapy for breast cancer therapy, palbociclib, marketed ...

In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T Biologics' ...

A comprehensive new review published in The Lancet affirms that currently approved mRNA vaccines are safe and highly ...

A bipartisan group of U.S. lawmakers opened national security investigations into whether five drugmakers including Merck and ...

(NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE ® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the ...